Biotoxtech Co. Ltd (086040) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.010x

Based on the latest financial reports, Biotoxtech Co. Ltd (086040) has a cash flow conversion efficiency ratio of -0.010x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-354.72 Million ≈ $-240.39K USD) by net assets (₩34.06 Billion ≈ $23.08 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Biotoxtech Co. Ltd balance sheet independence to measure how much of total assets are equity-financed.

Biotoxtech Co. Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)

This chart illustrates how Biotoxtech Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Biotoxtech Co. Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Biotoxtech Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Biotoxtech Co. Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
4Sight Holdings Ltd JSE:4SI	0.014x
Beasley Broadcast Group Inc NASDAQ:BBGI	0.064x
Dyandra Media International PT JK:DYAN	-0.037x
Fu Burg Industrial Co Ltd TWO:8929	0.001x
Advance Metals Ltd AU:AVM	-0.047x
Independence Gold Corp V:IGO	-0.075x
Amanet Management & Systems Ltd TA:AMAN	0.066x
U10 SA PA:ALU10	0.340x

Annual Cash Flow Conversion Efficiency for Biotoxtech Co. Ltd (2011–2024)

The table below shows the annual cash flow conversion efficiency of Biotoxtech Co. Ltd from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Biotoxtech Co. Ltd (086040) total market value.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩40.08 Billion ≈ $27.16 Million	₩-7.12 Billion ≈ $-4.83 Million	-0.178x	+47.23%
2023-12-31	₩48.23 Billion ≈ $32.69 Million	₩-16.24 Billion ≈ $-11.00 Million	-0.337x	-1037.55%
2022-12-31	₩44.23 Billion ≈ $29.98 Million	₩-1.31 Billion ≈ $-887.16K	-0.030x	-128.02%
2021-12-31	₩41.14 Billion ≈ $27.88 Million	₩4.35 Billion ≈ $2.95 Million	0.106x	-22.40%
2020-12-31	₩33.53 Billion ≈ $22.72 Million	₩4.56 Billion ≈ $3.09 Million	0.136x	+184.65%
2019-12-31	₩30.19 Billion ≈ $20.46 Million	₩1.44 Billion ≈ $978.48K	0.048x	-51.17%
2018-12-31	₩31.25 Billion ≈ $21.18 Million	₩3.06 Billion ≈ $2.07 Million	0.098x	-56.77%
2017-12-31	₩26.59 Billion ≈ $18.02 Million	₩6.02 Billion ≈ $4.08 Million	0.227x	+5.24%
2016-12-31	₩24.54 Billion ≈ $16.63 Million	₩5.28 Billion ≈ $3.58 Million	0.215x	+736.12%
2015-12-31	₩23.58 Billion ≈ $15.98 Million	₩-798.17 Million ≈ $-540.91K	-0.034x	+55.89%
2014-12-31	₩26.68 Billion ≈ $18.08 Million	₩-2.05 Billion ≈ $-1.39 Million	-0.077x	-221.95%
2012-12-31	₩25.93 Billion ≈ $17.57 Million	₩1.63 Billion ≈ $1.11 Million	0.063x	-58.32%
2011-12-31	₩21.74 Billion ≈ $14.73 Million	₩3.28 Billion ≈ $2.22 Million	0.151x	--

About Biotoxtech Co. Ltd

KQ:086040 Korea Biotechnology & Medical Research

Market Cap

$21.01 Million

₩31.01 Billion KRW

Market Cap Rank

#24917 Global

#1795 in Korea

Share Price

₩2130.00

Change (1 day)

+2.90%

52-Week Range

₩1983.00 - ₩3925.00

All Time High

₩23000.00